Pharmacogenetics and personalized medicine: The future for drug prescribing

Journal Medical Libanais

Volumn 58, Issue 2, 2010, Pages 101-104

  Mitri, Zahi ^b   Esmerian, Maria O ^b   Simaan, Joseph A ^b   Sabra, Ramzi ^b   Zgheib, Nathalie Khoueiry ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; CYTOCHROME P450 2C9; DNA; WARFARIN; CYTOCHROME P450; VITAMIN K GROUP; AMITRIPTYLINE; CELECOXIB; CITALOPRAM; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DIAZEPAM; DICLOFENAC; DRUG METABOLIZING ENZYME; FLUINDOSTATIN; FLUOXETINE; IBUPROFEN; IMIPRAMINE; LOSARTAN; NAPROXEN; NELFINAVIR; OMEPRAZOLE; OXIDOREDUCTASE; PHENYTOIN; PROPRANOLOL; RABEPRAZOLE; TOLBUTAMIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL RESEARCH; DNA SEQUENCE; DRUG EFFICACY; DRUG TARGETING; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEBANON; LONG TERM CARE; MAJOR CLINICAL STUDY; PERSONALIZED MEDICINE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ARTICLE; DRUG ANTAGONISM; GENETICS; DRUG METABOLISM; DRUG PROTEIN BINDING; GENE FREQUENCY; GENE TARGETING; GENETIC VARIABILITY; GENOTYPING TECHNIQUE;

ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LEBANON; PHARMACOGENETICS; VITAMIN K;

EID: 77954926600     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics : the promise of personalized medicine. AAPS PharmSci 2000; 2 : E4.
2. Shah R. Pharmacogenetics in drug regulation : promise, potential and pitfalls. Phil Trans R Soc B 2005; 360 : 1617-38.
3. Pirazzoli A, Recchia G. Pharmacogenetics and pharmacogenomics : are they still promising ? Pharmacological Research 2004; 49 : 357-61. (Pubitemid 38175333)
4. Roth M. Senator Obama introduces genomics and personalized medicine act of 2006. http://www.nixonpeabody.com/publications-detail3.asp?ID=1461 (Accessed Jan 20, 2007)
5. Ruano G. Quo vadis personalized medicine ? Future Medicine 2004; 1 : 1-7.
6. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics : a regulatory perspective. Nat Rev Drug Discov 2004; 3 : 763-9. (Pubitemid 39242828)
7. Leeder JS. Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 2004; 9 : 567-73. (Pubitemid 38760180)
8. Lanfear DE, McLeod HL. Pharmacogenetics : using DNA to optimize drug therapy. Am Fam Physician 2007; 76 : 1179-82. (Pubitemid 350033897)
9. Guidance for Industry : Pharmacogenetic Data Submissions. http://www.fda.gov/CbER/gdlns/pharmdtasub.pdf (Accessed Jan 20, 2007)
10. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72 : 702-10. (Pubitemid 36021009)
11. Flockhart DA. Cytochrome P450 Drug Interaction Table. http://medicine.iupui.edu/flockhart/table.htm. (Accessed Jan 20, 2009)
12. Ingelman-Sundberg M, Daly A K, Nebert DW. Human Cytochrome P450 (CYP) Allele nommenclature. www.imm.ki.se/CYPalleles. (Accessed Jan 20, 2009)
13. Campos-Outcalt D. Personalized medicine : the promise, the reality. J Fam Pract 2007; 56 : 621-6.
14. Omer B, Ozbek U, Akkose A, Kilic G. Genetic polymorphism of cytochrome P450 2E1 in the Turkish population. Cell Biochem Funct 2001; 19 : 273-5. (Pubitemid 33097883)
15. Ahmet OA, Sinan HS, Mumtaz I. Polymorphisms of cytochrome P450 1A1, glutathione S-transferase M1 and T1 in a Turkish population. Toxicology Letters 2004.
16. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene : impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284 : 455-60. (Pubitemid 32917998)
17. Aynacioglu AS, Brockmoller J, Bauer S et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48 : 409-15. (Pubitemid 29417726)
18. Hamdy SI, Hiratsuka M, Narahara K et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002; 53 : 596-603. (Pubitemid 34621785)
19. Babaoglu MO, Yasar U, Sandberg M et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004; 60 : 337-42. (Pubitemid 39066253)
20. Hamdy SI, Hiratsuka M, Narahara K et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003; 55 : 321-4. (Pubitemid 36390765)
21. Hamdy SI, Hiratsuka M, Narahara K et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 2003; 55 : 560-9. (Pubitemid 36783197)
22. Tayeb MT, Clark C, Ameyaw MM et al. CYP3A4 promoter variant in Saudi, Ghanain and Scottish Caucasian populations. Pharmacogenetics 2000; 10 : 753-6.
23. Peyvandi F, Spreafico M, Karimi M, Zeinali S, Mannucci PM, Bianchi BA. Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb Haemost 2002; 88 : 874-5. (Pubitemid 35345350)
24. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004; 75 : 198-203. (Pubitemid 38314869)
25. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77 : 1-16. (Pubitemid 40089477)
26. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449 : 851-61.
27. McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007; 3 : 751-9. (Pubitemid 350162075)